Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge. And pharma isn’t treating it like one yet.

An exclusive conversation with OpenAI’s chief scientist Jakub Pachocki about his firm's new grand challenge and the future of AI.

Required reading if you loved the Barbie star’s latest movie ...